Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Glucagonoma
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
- Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
- Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors